As the S&P 500 seeks the next leg higher, smart money might be moving toward healthcare, a sleeper sector of 2026.

While technology valuations trade at a premium to historical averages, healthcare has remained a relative laggard. Despite BlackRock's optimism in January, after the first third of the year, the sector has underperformed. The Vanguard Health Care Index Fund (NYSE:VHT) is down 5.50% year-to-date.

Still, the series of earnings upgrades, coupled with an AI-driven drug-discovery tailwind, suggests the sector is no longer just a defensive play. It is shaping into a growth engine that the broad market is yet to fully acknowledge.

The April Surge

The latest earnings cycle confirms the shift. On Tuesday, UnitedHealth (NYSE:UNH) raised full-year guidance following a strong first quarter. Despite short-term pressure, the fundamental outlook for the leading insurer continues to strengthen as it integrates advanced analytics into its claim processing.

Meanwhile, on Thursday, Eli Lilly (NYSE:LLY) raised its guidance for both revenue and profit, boosting the FY revenue by $2 billion, to $82-85 billion. Simultaneously, Merck (NYSE:MRK) tightened its revenue guidance to the upper end of its range, $65.8-$67 billion, after a strong Q1.

Perhaps most notably, Johnson & Johnson (NYSE:JNJ) raised its guidance above $100 billion for the first time in the company’s history.

Beyond The Spreadsheet

One key component of this hidden healthcare value is the integration of generative AI into the drug discovery process. While the market often views AI as a back-office cost-saver, industry leaders see it as a “discovery-accelerator.”

A recent $2.75 billion deal between Eli Lilly and Insilico Medicine is a top example of how lucrative healthcare AI can be. According to deal terms, Lilly will gain an exclusive worldwide license for "development, manufacturing, and commercialization of potentially best-in-class, novel oral therapeutics in preclinical development for certain indications." By using Insilico's "Pharma.AI" platform, Lilly can identify multi-purpose targets that drive complex diseases and accelerate the identification of promising therapeutic candidates.

A Rotation Underway

Recent flow data indicate that institutional capital is already moving. TradePulse data shows  that, while semiconductor and technology hardware exposure remains consistent, healthcare is expanding with names like Novo Nordisk (NYSE:NVO) and Centene (NYSE:CNC) seeing increased participation.

Although this research also shows that some healthcare names exhibit negative short-term momentum, high flow scores suggest institutional money might use volatility to build positions.

Thus, once the market recognizes the significant value gap between using AI to generate memes or write student essays and formulating life-saving treatments, the healthcare sector's sleeper status might rapidly evaporate.

Image: Shutterstock